Lilly's experimental 'triple' drug beats Ozempic in a big diabetes trial
Published
In a 1,298-person study, people taking retatrutide lost about 20% of their body weight over 80 weeks, roughly twice as much as with semaglutide, and saw bigger drops in blood sugar. More people quit retatrutide because of side effects. The drug is not approved yet, and Lilly hasn't given an approval timeline.
Source: AJMC
This is a plain-language summary. Read the original source for full details.